A Phase 1, Placebo-controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Iv Doses Of Pf-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2015
At a glance
- Drugs PF 5231023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 06 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.